Micardis licence extended

Micardis (telmisartan) can now be prescribed for the prevention of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke or peripheral arterial disease), or type 2 diabetes with documented target organ damage.

The recommended dose for this indication is 80mg once daily.

View Micardis drug record

Further information: Boehringer Ingelheim

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more